http://urologytimes.modernmedicine.com/urologytimes/BPH/Article/list/9400 Treatment and research news and developments about benign prostatic hyperplasia (BPH) and prostatitis. 2009-11-21T08:58:37Z http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Majority-of-nocturia-patients-have-nocturnal-polyu/ArticleStandard/Article/detail/637925?contextCategoryId=9400&ref=25 A study shows that most patients with nocturia have nocturnal polyuria, which is consistent with other studies showing that overproduction of urine at night is a major contributory factor to nocturia in about 80% of patients. 2009-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442009/637925null XML http://urologytimes.modernmedicine.com/urologytimes/Urinary+Incontinence%2FOveractive+Bladder/Majority-of-nocturia-patients-have-nocturnal-polyu/ArticleStandard/Article/detail/638690?contextCategoryId=9400&ref=25 Drs. Shlomo Raz and Ja-Hong Kim discuss recent advances in the treatment of stress incontinence. 2009-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/452009/638690null REMOTE http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Two-thirds-of-BPHLUTS-patients-dont-receive-meds/ArticleStandard/Article/detail/624485?contextCategoryId=9400&ref=25 BPH and lower urinary tract symptoms are very common, increase as a function of age, and are often managed through watchful waiting. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624485null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Study-Light-activated-BPH-therapy-safe-painless/ArticleStandard/Article/detail/624465?contextCategoryId=9400&ref=25 Light-activated drug therapy for BPH has been shown to be safe and painless in a phase I/II trial. 2009-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372009/624465null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/BPH-related-symptoms-improve-with-PDE-5-inhibitor/ArticleStandard/Article/detail/602359?contextCategoryId=9400&ref=25 Findings from a multicenter, randomized, double-blind, placebo-controlled study are consistent with previously reported data showing that tadalafil (Cialis) improves lower urinary tract symptoms associated with BPH. 2009-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/242009/602359null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Two-drug-therapy-effective-in-lower-urinary-tract-/ArticleStandard/Article/detail/595583?contextCategoryId=9400&ref=25 Anticholinergic drugs also are effective and safe in men who have lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) secondary to BPH, a new study suggests. 2009-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/182009/595583null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/New-alpha-blocker-highly-selective-for-urinary-tra/ArticleStandard/Article/detail/595562?contextCategoryId=9400&ref=25 A new alpha-blocker for the treatment of BPH shows positive results with minimal cardiovascular side effects, according to a presentation made during the European Association of Urology annual congress 2009-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/182009/595562null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Injectable-agents-may-expand-options-for-BPH/ArticleStandard/Article/detail/595548?contextCategoryId=9400&ref=25 While medical therapy remains the mainstay of treatment for most men with symptomatic BPH and surgery is required for severe, progressive disease, injectables may offer a number of theoretical advantages. 2009-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/182009/595548null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Targeted-BPH-treatment-safe-effective-at-1-year/ArticleStandard/Article/detail/595551?contextCategoryId=9400&ref=25 Transperineal intraprostatic injection of a PSA-activated protoxin (PRX302) provides lasting symptomatic relief and improvement in quality of life for men with BPH, according to 1-year follow-up data from a phase I study. 2009-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/182009/595551null XML http://urologytimes.modernmedicine.com/urologytimes/Modern+Medicine+Now/Alpha-blocker-then-TWOC-Global-standard-for-acute-/ArticleStandard/Article/detail/595547?contextCategoryId=9400&ref=25 The largest worldwide survey of acute urinary retention (AUR) ever performed suggests treatment with an alpha-blocker and trial without catheter (TWOC) within 3 days after AUR is the worldwide standard of care. 2009-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/182009/595547null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Creating-a-New-Standard-of-Care-for-BPH/ArticleStandard/Article/detail/589435?contextCategoryId=9400&ref=25 Creating a New Standard of Care for BPH Supplement for April 15, 2009 Urology Times Issue 2009-03-25T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/132009/589435null PDF http://www.modernmedicine.com/modernmedicine/BPH/Transurethral-resection-of-the-prostate-photoselec/ArticleStandard/Article/detail/548542?contextCategoryId=9400&ref=25 Men facing treatment for benign prostatic hyperplasia can expect similar outcomes after transurethral resection of the prostate or photoselective vaporization of the prostate. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548542null XML http://www.modernmedicine.com/modernmedicine/News/Benign-prostatic-hyperplasia-symptoms-quality-of-l/ArticleStandard/Article/detail/548543?contextCategoryId=9400&ref=25 A single injection of a bacterial protoxin activated by prostate-specific antigen led to greater than 50 percent improvement in symptoms within 3 months in a preliminary clinical study of men with benign prostatic hyperplasia. 2008-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/372008/548543null XML http://urologytimes.modernmedicine.com/urologytimes/Enews/NIDDK-publishes-strategic-plan-for-benign-prostate/ArticleStandard/Article/detail/534933?contextCategoryId=9400&ref=25 For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases. 2008-08-14T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/332008/534933null HTML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/Finasteride-supported-as-chemoprevention-in-prosta/ArticleStandard/Article/detail/534004?contextCategoryId=9400&ref=25 Leading European urologists have reviewed the findings from the Prostate Cancer Prevention Trial (PCPT) and have reached consensus supporting the use of finasteride (Proscar) as a chemopreventive agent for the disease. A similar consensus statement in the United States appears to be coming soon. 2008-08-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/322008/534004null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/FDA-gives-nod-to-combination-treatment-for-BPH/ArticleStandard/Article/detail/525994?contextCategoryId=9400&ref=25 FDA has approved the 5-alpha-reductase inhibitor dutasteride (Avodart) in combination with the alpha-blocker tamsulosin (Flomax) for treatment of symptomatic enlarged prostate. Both drugs had previously been approved individually for treatment of enlarged prostate. 2008-06-26T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/262008/525994null HTML http://www.modernmedicine.com/modernmedicine/News/Alpha-blocker-raises-success-of-trial-without-cath/ArticleStandard/Article/detail/520522?contextCategoryId=9400&ref=25 A trial without catheter (TWOC) following an average of 3 days of catheterization has become standard practice in men with acute urinary retention (AUR) associated with BPH. Now, the results of a recent study have shown that the administration of an alpha-blocker prior to a TWOC can significantly increase the chances of the success of TWOC. 2008-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232008/520522null XML http://www.modernmedicine.com/modernmedicine/News/Therapy-combination-superior-in-high-risk-BPH-pati/ArticleStandard/Article/detail/520517?contextCategoryId=9400&ref=25 The combination of dutasteride (Avodart) and tamsulosin (Flomax) provides significantly greater improvement in International Prostate Symptom Score (IPSS) and patient-reported quality of life than either therapy alone in men with BPH who are at increased risk of progression. 2008-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232008/520517null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Two-drug-combination-superior-in-high-risk-BPH-pat/ArticleStandard/Article/detail/518415?contextCategoryId=9400&ref=25 The combination of dutasteride (Avodart) and tamsulosin (Flomax) provides significantly greater improvement in International Prostate Symptom Score (IPSS) and patient-reported quality of life than either therapy alone in men with BPH who are at increased risk of progression, according to a 2-year analysis of data from the 4-year Combination of Avodart and Tamsulosin (CombAT) trial. 2008-05-21T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/212008/518415null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/TURP-PVP-show-comparable-efficacy-in-apples-to-app/ArticleStandard/Article/detail/518435?contextCategoryId=9400&ref=25 Men facing treatment for BPH can expect similar outcomes after transurethral resection of the prostate (TURP) or photoselective vaporization of the prostate (PVP), according to results of a multicenter head-to-head comparison of the two treatments, presented at the AUA annual meeting. 2008-05-21T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/212008/518435null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/Alpha-blocker-raises-success-of-trial-without-cath/ArticleStandard/Article/detail/518417?contextCategoryId=9400&ref=25 A trial without catheter (TWOC) following an average of 3 days of catheterization has become standard practice in men with acute urinary retention (AUR) associated with BPH. Now the results of a study presented here have shown that the administration of an alpha-blocker prior to a TWOC can significantly increase the chances of TWOC success. 2008-05-21T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/212008/518417null HTML http://urologytimes.modernmedicine.com/urologytimes/Online+Only/New-in-office-BPH-laser-treatment-is-efficient-cos/ArticleStandard/Article/detail/517898?contextCategoryId=9400&ref=25 Biolitec has launched the 150-watt Evolve side-firing diode laser unit, which the company says precisely ablates and coagulates prostate tissue, resulting in shorter procedures and recovery times. 2008-05-19T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/212008/517898null HTML http://urologytimes.modernmedicine.com/urologytimes/Online+Only/Use-of-minimally-invasive-BPH-treatments-up-signif/ArticleStandard/Article/detail/517576?contextCategoryId=9400&ref=25 Use of minimally invasive surgical treatments (MISTs) for BPH has increased tremendously in the past decade, but urologists should be careful about overusing these newer technologies, given the lack of long-term evidence of their efficacy, researchers from the University of Minnesota said here. 2008-05-17T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/202008/517576null HTML http://www.modernmedicine.com/modernmedicine/BPH/TURP-Superior-results-confirm-value-in-treating-BP/ArticleStandard/Article/detail/515199?contextCategoryId=9400&ref=25 A leading BPH researcher has presented data demonstrating the persistent value and utility of a time-tested treatment: monopolar transurethral resection of the prostate. 2008-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/192008/515199null XML http://www.modernmedicine.com/modernmedicine/News/Phytotherapy-to-treat-BPH-Selective-success-or-fut/ArticleStandard/Article/detail/515194?contextCategoryId=9400&ref=25 Although much of the argument supporting phytotherapy for lower urinary tract symptoms and BPH is flawed, this therapy appears to work well enough to make it a viable choice for patients with moderate symptoms and low bother scores. 2008-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/192008/515194null XML http://www.modernmedicine.com/modernmedicine/BPH/KTP-laser-shows-good-results-in-BPH-at-4-years/ArticleStandard/Article/detail/515201?contextCategoryId=9400&ref=25 Treatment of lower urinary tract symptoms using an 80-watt laser prostatectomy system showed a significant decrease in IPSS and post-void residual urine, among other positive indicators. 2008-05-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/192008/515201null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Two-injectable-BPH-drugs-reach-clinical-trial-mile/ArticleStandard/Article/detail/511627?contextCategoryId=9400&ref=25 Two injectable drugs for the treatment of BPH are approaching critical milestones: one, a phase II trial of the investigational drug NX-1207; the other, enrollment in the first of three multicenter phase III trials of cetrorelix. 2008-04-24T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/172008/511627null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/Botulinum-toxin-may-trigger-severe-adverse-reactio/ArticleStandard/Article/detail/494609?contextCategoryId=9400&ref=25 FDA has received reports of systemic adverse reactions, including respiratory compromise and death following the use of botulinum toxins types A (Botox) and B (BotoMyobloc) for FDA-approved and unapproved uses. The reactions reported are suggestive of botulism, the agency said. 2008-02-28T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/092008/494609null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/Risk-of-BPH-may-decrease-with-low-fat-diet/ArticleStandard/Article/detail/494601?contextCategoryId=9400&ref=25 A diet low in fat and red meat but high in vegetables and lean protein may significantly decrease the risk of symptomatic BPH, according to researchers at the Fred Hutchinson Cancer Research Center in Seattle. 2008-02-28T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/092008/494601null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/Two-drug-therapy-improves-BPH-symptoms/ArticleStandard/Article/detail/486689?contextCategoryId=9400&ref=25 Men with BPH who take a combination of dutasteride (Avodart) and tamsulosin (Flomax) appear to experience significantly greater improvement in urinary symptoms than do men taking either medication alone, according to findings from the CombAT (Combination of Avodart and Tamsulosin) study. 2008-01-31T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/042008/486689null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/HoLEP-in-BPH-shows-safety-efficacy-durability/ArticleStandard/Article/detail/482231?contextCategoryId=9400&ref=25 Three studies suggest that holmium laser enucleation of the prostate (HoLEP) is efficacious and safe, and that outcomes are durable. 2008-01-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/022008/482231null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Prostate-doubling-time-may-be-valuable-prognostic-/ArticleStandard/Article/detail/482230?contextCategoryId=9400&ref=25 The pace of prostate growth in a majority of men of northern European descent is as steady as a ticking clock and gives clinicians the opportunity to forecast prostate size in many patients with a single ultrasound measurement. 2008-01-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/022008/482230null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/BPH-treatment-offers-promising-2-year-results/ArticleStandard/Article/detail/477269?contextCategoryId=9400&ref=25 An investigational therapy for BPH known as NX-1207 has shown positive results in a long-term outcome study, according to its manufacturer, Nymox Pharmaceutical Corp. 2007-12-06T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/492007/477269null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/AUR-may-foreshadow-increased-morbidity-mortality/ArticleStandard/Article/detail/475193?contextCategoryId=9400&ref=25 Clinicians confronting acute urinary retention (AUR) would do well to not only resolve the retention, but to also look for and treat comorbid disease, which amplifies the risk of death in a disease state already associated with a high incidence of mortality. 2007-12-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/482007/475193null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/BPH-treatment-arrests-prostate-growth-improves-sym/ArticleStandard/Article/detail/468961?contextCategoryId=9400&ref=25 Treatment with an investigational agent known as elocalcitol effectively arrested prostate growth in BPH patients, according to Italian researchers. The therapy also showed improvements in urgency, frequency, and nocturia. 2007-11-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/442007/468961null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/Combination-therapy-provides-continuous-BPH-sympto/ArticleStandard/Article/detail/458036?contextCategoryId=9400&ref=25 Combination treatment with the 5-alpha-reductase inhibitor dutasteride (Avodart) and the alpha-blocker tamsulosin (Flomax) provides significantly greater urinary symptom improvement for men with BPH than either therapy alone does over 24 months, according to a study presented at the recent meeting of the Société Internationale d’Urologie in Paris. 2007-09-20T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/382007/458036null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/Famed-basketball-coach-tours-nation-to-get-word-ou/ArticleStandard/Article/detail/453757?contextCategoryId=9400&ref=25 The Prostate Cancer Education Council, a nonprofit consortium of expert physicians, health educators, scientists, and prostate health advocates, is teaming with former Detroit Pistons basketball coach Chuck Daly to spread the word on prostate health issues. BPH Game Plan Starts with U, the culmination of their efforts, is a recently launched national initiative to promote screenings and to raise awareness of BPH. 2007-09-06T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/352007/453757null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/PDE-5-inhibitors-may-play-a-role-in-BPH-LUTS-treat/ArticleStandard/Article/detail/453749?contextCategoryId=9400&ref=25 The therapeutic role of phosphodiesterase type-5 inhibitors could expand to include some patients with BPH and lower urinary tract symptoms, according to findings from two studies presented at the AUA annual meeting in Anaheim, CA. 2007-09-06T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/352007/453749null HTML http://urologytimes.modernmedicine.com/urologytimes/Urology/Quality-of-life-is-primary-indicator-of-BPH-relate/ArticleStandard/Article/detail/454951?contextCategoryId=9400&ref=25 Of all the measurable factors a urologist must weigh when developing a prognosis for the patient with BPH, only health-related quality of life as assessed by the Benign Prostatic Hyperplasia Impact Index significantly raises the potential for surgical intervention. 2007-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/362007/454951null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/PDE-5-inhibitors-may-play-a-role-in-BPH-LUTS/ArticleStandard/Article/detail/454960?contextCategoryId=9400&ref=25 The therapeutic role of phosphodiesterase-5 (PDE-5) inhibitors could expand to include some patients with BPH and lower urinary tract symptoms. 2007-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/362007/454960null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Botulinum-toxin-appears-safe-effective-in-BPHLUTS/ArticleStandard/Article/detail/454961?contextCategoryId=9400&ref=25 Data from two Taiwanese studies presented at the 2007 AUA annual meeting on the use of botulinum toxin A (Botox) suggest that injections of the agent into the prostate are safe and effective in relieving the symptoms of BPH and that the treatment supplements the therapeutic benefits of medical treatment in men with larger glands. 2007-09-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/362007/454961null XML http://www.modernmedicine.com/modernmedicine/BPH/ED-drugs-may-offer-intriguing-therapy-for-BPHLUTS/ArticleStandard/Article/detail/449574?contextCategoryId=9400&ref=25 While urologists continue to search for the most effective means of treating BPH and lower urinary tract symptoms, research presented at the 2007 AUA annual meeting suggests that drugs they may already be prescribing for other conditions could provide a novel solution. 2007-08-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/332007/449574null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/New-laser-for-BPH-found-effective-safe-at-2-years/ArticleStandard/Article/detail/431401?contextCategoryId=9400&ref=25 A new continuous wave thulium laser device appears to offer a safe, bloodless, effective, and expeditious outpatient surgical procedure for men with BPH. 2007-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232007/431401null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Data-analysis-confirms-BPH-as-progressive-disease/ArticleStandard/Article/detail/431392?contextCategoryId=9400&ref=25 Results from a recent study that systematically analyzed the data of placebo-controlled trials in patients with BPH confirm that BPH is a progressive disease on the basis of worsening prostate volume, maximum urinary flow, and symptom score, as well as the rate of prostate-related surgery and acute urinary retention. 2007-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232007/431392null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Lap-technique-may-play-a-role-in-treating-BPH/ArticleStandard/Article/detail/431386?contextCategoryId=9400&ref=25 A laparoscopic preperitoneal approach cannot only serve as a teaching platform for laparoscopic skills for surgeons, but it also demonstrates reproducible outcomes in the treatment of BPH. 2007-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232007/431386null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/PVP-TURP-show-comparable-outcomes-at-2-years/ArticleStandard/Article/detail/431387?contextCategoryId=9400&ref=25 Data from two similarly designed European studies comparing photoselective vaporization of the prostate and transurethral resection of the prostate show similar outcomes after a 2-year follow-up in patients with lower urinary tract symptoms due to BPH. 2007-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232007/431387null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Minimally-invasive-treatments-for-BPH-offer-altern/ArticleStandard/Article/detail/427772?contextCategoryId=9400&ref=25 A number of minimally invasive treatments are allowing millions of men to avoid a lifetime of medications or major surgical intervention for treatment of BPH. 2007-05-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/202007/427772null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Company-challenges-medical-community-to-validate-b/ArticleStandard/Article/detail/404645?contextCategoryId=9400&ref=25 Verathon, Inc. (Bothell, WA) has issued a challenge to urology researchers: The company is offering $10,000 for the most practical and scientifically valid protocol to study the relationship of bladder wall mass and overactive bladder or BPH. The goal is to determine how bladder wall mass measurements can best be used in clinical practice. 2007-02-15T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/072007/404645null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/Protein-marker-related-to-severe-form-of-BPH/ArticleStandard/Article/detail/404633?contextCategoryId=9400&ref=25 Higher levels of a protein made by a gene known as JM-27 have been found in men whose BPH is more severe and more likely to lead to bladder-related complications if left untreated, according to Johns Hopkins researchers. The team, lead by Robert Getzenberg, PhD, also developed a blood test that detects the JM-27 protein in men with severe symptoms. 2007-02-15T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/072007/404633null HTML http://www.modernmedicine.com/modernmedicine/BPH/Daily-NSAID-use-may-protect-against-BPH-LUTS/ArticleStandard/Article/detail/401880?contextCategoryId=9400&ref=25 Rochester, MN—Men who take non-steroidal anti-inflammatory drugs (NSAIDs) daily have a decreased risk for developing BPH and associated lower urinary tract symptoms, according to analyses of data collected in a longitudinal population-based cohort study of aging men. 2007-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/052007/401880null XML http://urologytimes.modernmedicine.com/urologytimes/Enews/Investigational-drug-is-found-effective-safe-in-BP/ArticleStandard/Article/detail/401243?contextCategoryId=9400&ref=25 A course of the investigational drug silodosin, 8 mg once daily for 12 weeks, was superior to placebo for the relief of both obstructive and irritative symptoms in men with BPH, two phase III studies showed. Secondary endpoints included improvement in maximum urine flow. 2007-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/052007/401243null HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/Increased-fluid-intake-has-minimal-effect-on-male-/ArticleStandard/Article/detail/395480?contextCategoryId=9400&ref=25 Increased water intake may improve some aspects of bladder function in older men, but the effects are too small to be clinically relevant, according to a study by Dutch researchers. 2007-01-04T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/012007/395480null HTML http://www.modernmedicine.com/modernmedicine/Prostate+Cancer/Prostate-inflammation-not-a-predictor-of-cancer/ArticleStandard/Article/detail/395026?contextCategoryId=9400&ref=25 Chicago—Initial analyses from a retrospective study involving almost 600 men undergoing prostate needle biopsy show no association between inflammation on initial or subsequent biopsy and prostate cancer. However, the investigators from Harvard Medical School are withholding any conclusions while they continue their research. 2007-01-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/522006/395026null XML http://www.modernmedicine.com/modernmedicine/BPH/Combination-BPH-OAB-therapy-controls-symptoms/ArticleStandard/Article/detail/395018?contextCategoryId=9400&ref=25 New York—Men bothered by overactive bladder and prostate enlargement symptoms who are treated simultaneously with the anticholinergic drug tolterodine tartrate extended-release capsules (Detrol LA) and the alpha-blocker tamsulosin (Flomax) report better symptom control and quality of life than do men treated with either one of the medications or placebo, according to a recently published study (JAMA 2006; 296:2319-28). 2007-01-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/522006/395018null XML http://www.modernmedicine.com/modernmedicine/BPH/The-PVP-procedure-for-BPH-Long-term-outcomes/ArticleStandard/Article/detail/395028?contextCategoryId=9400&ref=25 PVP can be performed in inpatient and outpatient hospital settings, as well as in a well-equipped urology office in select patients. 2007-01-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/522006/395028/72020-c_thumbnail.jpg http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/522006/395028null XML http://www.modernmedicine.com/modernmedicine/BPH/Elevated-PSA-infection-are-most-predictive-of-AUR/ArticleStandard/Article/detail/390263?contextCategoryId=9400&ref=25 Ankara, Turkey—Elevated PSA levels and the presence of urinary tract infection are the symptomatic parameters that are most predictive of acute urine retention in men with BPH, according to a group of Turkish researchers. Their data also suggest that plasmakinetic resection of the prostate may provide 1-year outcomes similar to those of open prostatectomy in BPH patients who do not have retention. 2006-12-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/492006/390263null XML http://www.modernmedicine.com/modernmedicine/BPH/Intraprostatic-analgesic-may-improve-TUMT-outcomes/ArticleStandard/Article/detail/390267?contextCategoryId=9400&ref=25 Cleveland—Intraprostatic injection of mepivacaine epinephrine through a specialized catheter reduces the need for analgesia, as well as treatment time and energy consumption in patients undergoing high-energy transurethral microwave thermotherapy (TUMT) for BPH, researchers reported here. 2006-12-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/492006/390267null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Combination-therapy-may-be-more-effective-for-LUTS/ArticleStandard/Article/detail/385981?contextCategoryId=9400&ref=25 Men with overactive bladder and lower urinary tract symptoms who receive combination therapy are more likely to report improvement in symptoms than those who receive only one medication, according to results of a study recently reported in JAMA (2006; 296:2319-28). 2006-11-16T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/462006/385981null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/Investigational-BPH-drug-shows-promise-in-phase-II/ArticleStandard/Article/detail/379720?contextCategoryId=9400&ref=25 Patients with BPH who were treated with the investigational drug NX-1207 showed a total pooled mean improvement of 9.35 points in the primary outcome endpoint of AUA Symptom Score values at 3 months, researchers from Nymox Pharmaceutical Corp. reported. 2006-10-19T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/422006/379720null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/NSAIDs-may-prevent-or-delay-enlarged-prostate/ArticleStandard/Article/detail/369920?contextCategoryId=9400&ref=25 Nonsteroidal anti-inflammatory drugs such as aspirin and ibuprofen may prevent or delay BPH, according to a study conducted by researchers at the Mayo Clinic, Rochester, MN. 2006-09-07T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/362006/369920null HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/Groups-issue-advisory-about-alpha-blockers-and-cat/ArticleStandard/Article/detail/369923?contextCategoryId=9400&ref=25 AUA, the American Society of Cataract and Refractive Surgery, and the American Academy of Ophthalmology have advised patients taking alpha-blockers for BPH treatment to inform their eye surgeon about the drugs before undergoing eye surgery. 2006-09-07T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/362006/369923null HTML http://www.modernmedicine.com/modernmedicine/BPH/PDE-5-inhibitors-antimuscarinics-may-play-role-in-/ArticleStandard/Article/detail/366769?contextCategoryId=9400&ref=25 In men with BPH, drugs indicated for other urologic conditions may play a role in the treatment of their lower urinary tract symptoms, suggest data from a number of studies presented at the 2006 AUA annual meeting. These studies were among those on BPH and LUTS highlighted by Claus G. Roehrborn, MD, professor and chairman of the department of urology at the University of Texas Southwestern Medical Center, Dallas. 2006-08-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/342006/366769null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/FDA-grants-approval-to-generic-finasteride/ArticleStandard/Article/detail/354724?contextCategoryId=9400&ref=25 Teva Pharmaceutical Industries Ltd. has received final FDA approval to market a generic formulation of finasteride tablets, 5 mg. 2006-07-06T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/272006/354724null HTML http://www.modernmedicine.com/modernmedicine/BPH/Botulinum-toxin-A-shows-efficacy-in-treating-BPH/ArticleStandard/Article/detail/357756?contextCategoryId=9400&ref=25 Atlanta—Intraprostatic injection of botulinum toxin A (Botox) is a safe and effective treatment in patients with symptomatic BPH that results in improvements in symptoms and quality of life that may persist for up to 1 year, Chinese researchers reported at the AUA annual meeting here. 2006-07-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/282006/357756null XML http://www.modernmedicine.com/modernmedicine/BPH/Combo-therapy-packs-double-punch-against-LUTS-ED/ArticleStandard/Article/detail/357762?contextCategoryId=9400&ref=25 Atlanta—Combining an alpha-blocker with a phosphodiesterase-5 (PDE-5) inhibitor appears to produce a greater therapeutic benefit in men with lower urinary tract symptoms than either drug alone, according to a study from Weill Cornell Medical College, New York. 2006-07-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/282006/357762null XML http://www.modernmedicine.com/modernmedicine/BPH/TUMT-found-effective-in-treating-LUTS-at-8-years/ArticleStandard/Article/detail/333592?contextCategoryId=9400&ref=25 Paris—In patients with lower urinary tract symptoms due to bladder outlet obstruction, targeted high-energy transurethral microwave thermotherapy (TUMT) provides a suitable option for improvement of their condition, according to Bob Djavan, MD, who presented the results of an 8-year, multicenter, European study at the European Association of Urology annual congress here. 2006-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232006/333592null XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Investigational-drug-for-BPH-shows-promise-in-phas/ArticleStandard/Article/detail/330486?contextCategoryId=9400&ref=25 The investigational drug NX-1207 has shown significant symptomatic improvement in men with BPH 29 to 34 months after initial treatment in a long-term, open-label, phase I/II study. 2006-06-01T04:00:00Z HTML http://www.modernmedicine.com/modernmedicine/BPH/Microwave-therapy-may-challenge-TURP-in-treating-B/ArticleStandard/Article/detail/333591?contextCategoryId=9400&ref=25 Paris—Microwave thermotherapy is a safe, noninvasive treatment modality that challenges transurethral resection of the prostate as a first-line choice of treatment in patients with BPH, Scandinavian researchers said here at the European Association of Urology annual congress. 2006-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232006/333591null XML http://www.modernmedicine.com/modernmedicine/BPH/Effects-of-LUTS-similar-to-those-of-severe-disease/ArticleStandard/Article/detail/333594?contextCategoryId=9400&ref=25 Atlanta—Epidemiologic studies have a tendency to raise as many questions as they answer. A large study emanating from the Watertown, MA-based New England Research Institutes (NERI), an independent research organization, is an example. 2006-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232006/333594null XML http://www.modernmedicine.com/modernmedicine/BPH/Higher-BMI-is-associated-with-more-severe-BPH/ArticleStandard/Article/detail/333595?contextCategoryId=9400&ref=25 Paris—Significant statistical correlations are seen between body mass index (BMI) and BPH symptoms, according to Claus G. Roehrborn, MD, who led a global 4-year treatment study evaluating the relationships of BMI and both measures of lower urinary tract symptoms (LUTS)/BPH severity and metabolic syndrome. Results of the study were presented at the European Association of Urology annual congress here. 2006-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232006/333595null XML http://www.modernmedicine.com/modernmedicine/BPH/Once-daily-alpha-blocker-curbs-BPH-symptoms/ArticleStandard/Article/detail/333593?contextCategoryId=9400&ref=25 Paris—Once-daily administration of a newer alpha-blocker appears to have a positive effect in the treatment of patients suffering from lower urinary tract symptoms and BPH compared with placebo, but comes up short in preventing acute urinary retention occurrence, according to Claus G. Roehrborn, MD, professor and chairman of the department of urology at the University of Texas Southwestern Medical Center, Dallas. Dr. Roehrborn presented the results of a 2-year study at the European Association of Urology annual congress here. 2006-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232006/333593null XML http://www.modernmedicine.com/modernmedicine/BPH/Pre-TWOC-alpha-blocker-reduces-urinary-retention-r/ArticleStandard/Article/detail/333590?contextCategoryId=9400&ref=25 Paris—Trial without catheter (TWOC) after a median of 3 days' catheterization has become standard practice in France for patients with acute urinary retention associated with BPH, according to results of a prospective, cross-sectional survey assessing current AUR practice patterns. In addition, TWOC was significantly more successful in patients who received treatment with an alpha-blocker prior to a TWOC than it was in patients who did not receive an alpha-blocker, according to Francois Desgrandchamps, MD, who presented the study results at the European Association of Urology annual congress here. 2006-06-01T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/232006/333590null XML http://www.modernmedicine.com/modernmedicine/BPH/PSA-TRUS-data-reflect-adequacy-of-BPH-treatments/ArticleStandard/Article/detail/328145?contextCategoryId=9400&ref=25 Brisbane, Australia—Declines in PSA levels and transrectal ultrasound prostate volume appear to be useful when evaluating endoscopic treatment techniques for BPH that do not retrieve tissue, according to New Zealand researchers. 2006-05-15T04:00:00Z XML http://www.modernmedicine.com/modernmedicine/BPH/Large-scale-BPH-studies-Data-are-forthcoming/ArticleStandard/Article/detail/328143?contextCategoryId=9400&ref=25 The major discussions of advances in understanding and treating BPH may take place in the hallways rather than in the official meeting rooms during this month's AUA annual meeting, Claus G. Roehrborn, MD, professor and chairman of the department of urology at the University of Texas Southwestern Medical Center, Dallas, told Urology Times. 2006-05-15T04:00:00Z XML http://urologytimes.modernmedicine.com/urologytimes/BPH/New-control-unit-available-for-BPH-therapy/ArticleStandard/Article/detail/323826?contextCategoryId=9400&ref=25 Urologix, Inc., has received FDA approval to market its CoolWave control unit for use with its catheter-based treatments that use microwave technology to treat BPH. 2006-05-04T04:00:00Z HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/Saw-palmetto-takes-a-hit-in-long-term-BPH-study/ArticleStandard/Article/detail/308055?contextCategoryId=9400&ref=25 The popular herbal therapy saw palmetto appears to be no more effective than placebo for relieving symptoms of BPH, according to a year-long, double-blind study published last week in the New England Journal of Medicine (2006; 354:557-66). 2006-02-16T05:00:00Z HTML http://www.modernmedicine.com/modernmedicine/BPH/Genetics-and-inherited-prostate-cancer-risk/ArticleStandard/Article/detail/301392?contextCategoryId=9400&ref=25 Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among men in the United States.1 2006-02-01T05:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/conturo/052006/301392/i2_thumbnail.jpg XML http://urologytimes.modernmedicine.com/urologytimes/BPH/FDA-clears-laser-device-for-BPH/ArticleStandard/Article/detail/284340?contextCategoryId=9400&ref=25 Trimedyne, Inc., Irvine, CA, has received FDA approval to market its VaporMAX Fiber for use with its Holmium lasers to treat BPH. 2006-01-19T05:00:00Z HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/CMS-revises-reimbursement-for-in-office-BPH-proced/ArticleStandard/Article/detail/284350?contextCategoryId=9400&ref=25 Laserscope, San Jose, CA, has announced that the Centers for Medicare & Medicaid Services has published a technical revision to the 2006 Medicare physician few schedule. 2006-01-19T05:00:00Z HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/Former-NBA-star-heads-campaign-to-educate-men-abou/ArticleStandard/Article/detail/262609?contextCategoryId=9400&ref=25 Former New York Knicks basketball star Earl "The Pearl" Monroe is the point man for the "Flomax One-Week Challenge," a national campaign to educate men about BPH. 2005-12-16T05:00:00Z HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/Investigational-BPH-drug-shows-no-adverse-events-i/ArticleStandard/Article/detail/262562?contextCategoryId=9400&ref=25 A third interim safety analysis of an ongoing multicenter phase II trial of NX-1207, for the treatment of BPH, has revealed no serious side effects, according to Nymox Pharmaceutical Corp., the drug's manufacturer. 2005-12-16T05:00:00Z HTML http://urologytimes.modernmedicine.com/urologytimes/Enews/Revisions-made-to-alpha-blocker-prescribing-info/ArticleStandard/Article/detail/254384?contextCategoryId=9400&ref=25 Boehringer Ingelheim and the FDA have notified health care professionals of revisions to the precautions and adverse reactions sections of the prescribing information for tamsulosin hydrochloride (Flomax) for the treatment of BPH. 2005-12-01T05:00:00Z HTML http://www.modernmedicine.com/modernmedicine/News/Ultrasound-predicts-need-for-and-outcome-of-RP/ArticleStandard/Article/detail/257133?contextCategoryId=9400&ref=25 Montreal--Among men with BPH, an estimate of bladder weight using ultrasound can help predict both which patients will eventually require a prostatectomy and which ones will have favorable outcomes, according to researchers from the University of Fukui in Japan. Ultrasound-estimated bladder weight (USEBW) may provide a less-invasive alternative to current techniques. 2005-12-01T05:00:00Z XML http://www.modernmedicine.com/modernmedicine/BPH/BPH-Data-needed-to-sort-out-ideal-office-based-tre/ArticleStandard/Article/detail/197982?contextCategoryId=9400&ref=25 Paris--Minimally invasive and surgical treatments for BPH are poorly studied and lack standardized techniques, said Jean de la Rosette, MD, of the department of urology, University of Amsterdam. Dr. de la Rosette chaired a committee on these rapidly expanding treatment approaches at the International Consultation on New Developments in Prostate Cancer and Prostate Diseases. Therapies considered by the committee included transurethral microwave thermotherapy, transurethral needle ablation, transurethral resection of the prostate, water-induced thermotherapy, transurethral ethanol ablation of the prostate (TEAP), prosthetic stents, and lasers. 2005-11-01T05:00:00Z XML http://www.modernmedicine.com/modernmedicine/BPH/Terminology-regarding-LUTS-need-to-be-upgraded/ArticleStandard/Article/detail/197978?contextCategoryId=9400&ref=25 Paris--The term "lower urinary tract symptoms," or LUTS, is controversial because many urologists regard it as a replacement for prostatism, which focuses mainly on voiding dysfunction. But the most bothersome symptoms of LUTS relate to storage, said Christopher Chapple, MD. 2005-11-01T05:00:00Z XML http://www.modernmedicine.com/modernmedicine/BPH/BPH-progression-Prevention-is-determined-by-risk/ArticleStandard/Article/detail/197977?contextCategoryId=9400&ref=25 Paris--Although there is very little evidence for primary prevention of BPH and LUTS, evidence does exist for tertiary prevention after the condition is established, said Claus G. Roehrborn, MD, who chaired a committee on prevention of BPH outcomes at the International Consultation on New Developments in Prostate Cancer and Prostate Diseases. 2005-11-01T05:00:00Z XML http://www.modernmedicine.com/modernmedicine/BPH/30-minute-TUMT-unit-is-promising-for-BPH-relief/ArticleStandard/Article/detail/188390?contextCategoryId=9400&ref=25 Dallas--Interim data from a long-term study under way at five U.S. centers offer hope of enhanced relief for men with BPH. 2005-10-15T04:00:00Z XML http://www.modernmedicine.com/modernmedicine/BPH/Botulinum-toxin-shows-equivocal-results-in-BPH/ArticleStandard/Article/detail/188386?contextCategoryId=9400&ref=25 Scottsdale, AZ--Injecting botulinum toxin A (Botox) into the prostate gland shows potential for providing a quick, easy, and safe treatment option for men with lower urinary tract symptoms related to BPH, but two small studies—one from the United States and Chile, and one from Italy—provided equivocal results regarding the efficacy of this investigational approach. While the Italian data showed significant decreases in International Prostate Symptom Score and prostate size with botulinum toxin, U.S. researchers were unable to duplicate these results. Both studies were presented at the AUA annual meeting in San Antonio. 2005-10-15T04:00:00Z XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Prostate-vaporization-yields-good-long-term-result/ArticleStandard/Article/detail/184753?contextCategoryId=9400&ref=25 Men treated with photoselective vaporization of the prostate using the GreenLight laser system (Laserscope, San Jose, CA) for obstructive BPH achieve significant improvements in symptomatic and urodynamic outcomes at 5 years, according to a recently published study (J Urol 2005; 174:1344-8). 2005-10-06T04:00:00Z HTML http://www.modernmedicine.com/modernmedicine/Sexual+Dysfunction/Alpha-blockers-may-improve-erectile-dysfunction-in/ArticleStandard/Article/detail/185496?contextCategoryId=9400&ref=25 Denver--Studies in recent years have shown a strong correlation between lower urinary tract symptom severity and erectile dysfunction, but there have also been contradictory reports on the effect of BPH medications on sexual health. 2005-10-01T04:00:00Z XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Study-documents-effect-of-LUTS-on-erectile-functio/ArticleStandard/Article/detail/179171?contextCategoryId=9400&ref=25 A study presented at the AUA annual meeting confirmed what many urologists have suspected: The sexual health of men is affected by the severity of their lower urinary tract symptoms. 2005-09-07T04:00:00Z HTML http://urologytimes.modernmedicine.com/urologytimes/BPH/TUMT-is-found-safe-effective-alternative-to-surger/ArticleStandard/Article/detail/179172?contextCategoryId=9400&ref=25 Minimally invasive transurethral microwave thermotherapy using the ProstaLund Feedback Treatment system (PLFT; ProstaLund, Los Angeles) is a safe and effective alternative to surgery in patients with symptomatic BPH and persistent urinary retention, according to Scandinavian investigators. 2005-09-07T04:00:00Z HTML http://www.modernmedicine.com/modernmedicine/BPH/PSA-can-measure-prostate-size-in-true-BPH-patients/ArticleStandard/Article/detail/180309?contextCategoryId=9400&ref=25 San Antonio--PSA can be used to measure prostate size in patients with true BPH, according to a study using information from the Medical Therapy of Prostatic Symptoms (MTOPS) study. Claus G. Roehrborn, MD, and colleagues determined that in men with lower urinary tract symptoms and BPH, more than half of the PSA variability is due to prostate volume. 2005-09-01T04:00:00Z XML http://www.modernmedicine.com/modernmedicine/AUA+2005/TUMT-is-found-safe-effective-alternative-to-surger/ArticleStandard/Article/detail/180306?contextCategoryId=9400&ref=25 San Antonio--Minimally invasive transurethral microwave thermotherapy using the ProstaLund Feedback Treatment (PLFT; ProstaLund, Lund, Sweden) system is a safe and effective alternative to surgery in patients with symptomatic BPH and persistent urinary retention, regardless of prostate size, according to Scandinavian investigators. Their conclusion is based on a prospective, randomized, multicenter comparison study of the two approaches presented at the AUA annual meeting here. 2005-09-01T04:00:00Z XML http://www.modernmedicine.com/modernmedicine/BPH/Study-documents-effect-of-LUTS-on-erectile-functio/ArticleStandard/Article/detail/180302?contextCategoryId=9400&ref=25 San Antonio--A study presented here at the annual AUA meeting confirmed what many urologists have suspected: The sexual health of men is affected by the severity of their lower urinary tract symptoms. Researchers also found that sexual health declined with age, while African-American patients fared slightly worse than Caucasian patients in terms of sexual function. 2005-09-01T04:00:00Z XML http://www.modernmedicine.com/modernmedicine/AUA+2005/Rapidly-rising-PSA-levels-could-indicate-BPH/ArticleStandard/Article/detail/180308?contextCategoryId=9400&ref=25 San Antonio--A rapid increase in PSA level could be indicative of progressive benign prostatic hyperplasia if prostate cancer is ruled out. With the push for testing PSA levels in men at earlier ages, keeping BPH in mind when tracking results over time makes sense. 2005-09-01T04:00:00Z XML http://www.modernmedicine.com/modernmedicine/AUA+2005/Post-TUMT-symptom-improvement-persists-long-term/ArticleStandard/Article/detail/180307?contextCategoryId=9400&ref=25 San Antonio--Five-year follow-up data from the original FDA trial cohort demonstrate that transurethral microwave thermotherapy (TUMT) using the TherMatrx TMx-2000 (American Medical Systems, Minnetonka, MN) provides durable, safe treatment for men with symptomatic BPH. Study findings were presented by David M. Albala, MD, at the AUA annual meeting here. 2005-09-01T04:00:00Z XML http://urologytimes.modernmedicine.com/urologytimes/BPH/Campaign-directs-BPH-sufferers-to-urologists/ArticleStandard/Article/detail/175987?contextCategoryId=9400&ref=25 The Men's Health Network has launched the "The Back to Life Without Interruptions" educational campaign, designed to provide men with the tools they need to talk to their physician and partners about BPH-related problems. 2005-08-18T04:00:00Z HTML http://www.modernmedicine.com/modernmedicine/AUA+2005/BPH-data-reveal-key-findings-on-epidemiology-treat/ArticleStandard/Article/detail/177454?contextCategoryId=9400&ref=25 The 2005 AUA annual meeting in San Antonio proved to be fertile ground for research on both epidemiologic trends and clinical aspects of benign prostatic hyperplasia and lower urinary tract symptoms—medical therapy, minimally invasive treatments, and phytotherapy. Data from several key studies appeared to clarify the role of various treatment modalities in selected patient populations. Not all the news was positive, however, as one study showed no significant effect with saw palmetto, a commonly used herbal therapy. 2005-08-15T04:00:00Z http://urologytimes.modernmedicine.com/urologytimes/data/articlestandard/urologytimes/362005/177454/UTcoverAug15,05_6924_thumbnail.jpg XML http://urologytimes.modernmedicine.com/urologytimes/BPH/PSA-isoform-may-provide-more-specific-test-for-BPH/ArticleStandard/Article/detail/173459?contextCategoryId=9400&ref=25 An investigational laboratory test known as BPH-A may help identify BPH, researchers reported at a joint meeting of the International Federation of Clinical Chemistry and Laboratory Medicine and American Association for Clinical Chemistry in Orlando, FL. 2005-08-04T04:00:00Z HTML